The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.
Treg cell-based therapies: challenges and perspectives
Open accessAbstract
Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In this Review, we discuss the biology of Treg cells and describe new efforts in Treg cell engineering to enhance specificity, stability, functional activity and delivery. Finally, we envision that the success of Treg cell therapy in autoimmunity and transplantation will encourage the clinical use of adoptive Treg cell therapy for non-immune diseases, such as neurological disorders and tissue repair. Therapies based on adoptive cellular transfer of regulatory T (Treg) cells are currently undergoing clinical trials for autoimmune diseases, graft-versus-host disease and the prevention of transplant rejection. This Review provides an overview of Treg cell biology and discusses the latest approaches to enhance Treg cells for therapeutic purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Research works printed but not linked: 5
- Xia, G., He, J. & Leventhal, J. R. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am. J. Transpl. 8, 298–306 (2008). · doi:10.1111/j.1600-6143.2007.02088.x
- Jiang, S. et al. Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: potential reagents to promote donor-specific transplantation tolerance. Transplantation 82, 1738–1743 (2006). · doi:10.1097/01.tp.0000244932.29542.9e
- Goettel, J. A. et al. Low-dose interleukin-2 ameliorates colitis in a preclinical humanized mouse model. Cell Mol. Gastroenterol. Hepatol. 8, 193–195 (2019). · doi:10.1016/j.jcmgh.2019.05.001
- Boardman, D. A. & Levings, M. K. Cancer immunotherapies repurposed for use in autoimmunity. Nat. Biomed. Eng. 3, 259–263 (2019). · DOI
- Barton, A., John, S., Ollier, W. E., Silman, A. & Worthington, J. Association between rheumatoid arthritis and polymorphism of tumour necrosis factor receptor II, but not tumour necrosis factor receptor I, in Caucasians. Arthritis Rheum. 44, 61–65 (2001). · doi:10.1002/1529-0131(200101)44:1<61::aid-anr9>3.0.co;2-q
Cited by
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Wang, H., Zhang, H., Wang, Y., Brown, Z. J., Xia, Y., Huang, Z., Shen, C., Hu, Z., Beane, J., Ansa-Addo, E. A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.032 · Cited by 398
Metadata
- Authors
- Raffin, C., Vo, L. T., & Bluestone, J. A.
- Venue
- Nature Reviews Immunology
- Published
- 2019-12-06
- Volume
- 20
- Issue
- 3
- Pages
- 158-172
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2993022075
- Cited by
- 720
- References
- 234
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treg cell-based therapies: challenges and perspectives. https://app.cochat.ai/papers/10.1038/s41577-019-0232-6
- The paper
- Raffin, C., Vo, L. T., & Bluestone, J. A. (2020). Treg cell-based therapies: challenges and perspectives. Nature Reviews Immunology. https://doi.org/10.1038/s41577-019-0232-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
